
    
      To evaluate the activity of oral AB1010, administered at two dose levels during 12 weeks to
      patients with moderate to severe chronic plaque psoriasis, assessed on :

      i)Body Surface Area (BSA), Psoriasis Area and Severity Index (PASI), Overall Lesion Severity
      (OLS), Physician's Global Assessment (PGA) and Patient's Global Psoriasis Assessment (PGPA)
      ii)clinical and biological safety parameters iii) pharmacokinetic profile of AB1010
    
  